Disseminated mycobacterium avium on HIV/AIDS: Historical and current literature review
Telles, João Paulo Marochi; Muniz Júnior, Roberto; Sztajnbok, Jaques; Oliveira, André Cosme de.
AIDS reviews
; 22(1): 9-15, Jan.-Mar. 2020. tab, ilus
Artigo
Inglês
| SES-SP, SES SP - Instituto de Infectologia Emílio Ribas, SES-SP | ID: biblio-1087879
Combination antiretroviral therapy (cART) has changed Mycobacterium avium epidemiology. A significant decrease in the incidence of disseminated M. avium complex (DMAC) infection was observed between pre-cART and post-cART periods. In contrast, diagnoses of DMAC more than doubled from 1990 to 1996. During this time, DMAC prevalence in people living with AIDS (PLHA) in developed countries reached 20-23% overall and >40% in groups with CD4 cell counts <10 cells/mm3. At present, DMAC in PLHA has an incidence of two events per 1000 patient years. Recently, the centers for disease control changed the criteria for MAC primary prophylaxis, where only patients without immediate cART and CD4 cell counts <50 cells/mm3 are prescribed 1200 mg of azithromycin weekly. Treatment is discontinued when patients initiate effective cART. Diagnosing a disseminated M. avium infection is difficult due to the low accuracy of fluid cultures and a lack of diagnostic processes. However, the usefulness of newer molecular techniques such as whole-genome sequencing has not been evaluated for DMAC and HIV/AIDS. As DMAC has a high mortality rate if not properly diagnosed and treated, we performed a literature review of HIV/AIDS and DMAC epidemiology, risk factors, prophylaxis, clinical manifestation, diagnosis, prognosis, and treatment
Biblioteca responsável:
BR31.1
Localização: BR31.1; 2020_P-010
Texto completo
Documentos relacionados
